This framework describes the building blocks being laid down by the European Centre for Disease Prevention and Control (ECDC) to support and empower European Union (EU)/European Economic Area (EEA) countries and the European Commission in achieving microbial safety for substances of human origin (SoHO).
On 5 and 6 September, ECDC hosted the first joint SoHO-Net Tissues and Cells (TC) and Medically Assisted Reproduction (MAR) group meeting in Stockholm, Sweden.
This document provides an update on the safety of substances of human origin (SoHO) in relation to COVID-19. It reassesses the risk and proposes revised mitigation measures for preventing transmission through SoHO.
Repository of resources produced by national public health institutes, national ministries of health, or recognised and respected learned societies or academies.
Since the risk assessment published by ECDC in August 2021 on the risk of vCJD disease transmission via blood and PDMP manufactured from donations obtained in the UK, no new cases of vCJD associated with dietary exposure or transfusion of blood or blood components have been reported in EU/EEA or in the rest of the world.
ECDC assessed the risk to the EU/EEA of the presence and the possible transmission of prions, which have been linked to Creutzfeldt-Jakob disease, by blood and plasma-derived medicinal products (PDMPs) manufactured from donations obtained in the UK.
The European Centre for Disease Prevention and Control was asked by the European Commission to assess the risk involved in changing the testing requirements for HIV (human immunodeficiency virus), hepatitis B virus (HBV), and hepatitis C virus (HCV) with regard to the quality and safety of non-partner semen donations.